NCT06383182Recruiting
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion: a Prospective, Registry Study
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 17 Apr 2024
- Start date
- 2 Jul 2024
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- General Hospital of Shenyang Military Region
- Diseases
- Stroke
- NCT number
- NCT06383182
What you commit to
- Study type: Observational
- Planned participants: 800
- From 2 Jul 2024 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving intravenous thrombolysis;
Other illness
- Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage);
- Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg);
- Other conditions who are not suitable for this trial by investigator.
Lab values
- Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\<100×109/L);
- Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases;
Other
- The presence of contraindications to internal jugular vein cannulation;
- Pregnant or lactating women;
Who the study is looking for
- Age: 18-80 years;
- Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment;
- Pre-stroke mRS: 0-1;
- Baseline NIHSS: ≥6;
- Signed informed consent.
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| General Hospital of Northern Theater Command Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.